# HUMC 1612: Optune NovoTTF-200A System

> **NCT03128047** · PHASE1 · COMPLETED · sponsor: **Hackensack Meridian Health** · enrollment: 7 (actual)

## Conditions studied

- High Grade Glioma
- Ependymoma

## Interventions

- **DEVICE:** Optune NovoTTF-200A System

## Key facts

- **NCT ID:** NCT03128047
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-06
- **Primary completion:** 2024-07-08
- **Final completion:** 2025-04-05
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03128047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03128047, "HUMC 1612: Optune NovoTTF-200A System". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03128047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*